Kemp Dolliver
Stock Analyst at Brookline Capital
(0.50)
# 4,100
Out of 5,005 analysts
16
Total ratings
33.33%
Success rate
-17.31%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.19 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $6.20 | +190.32% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.52 | +1,169.84% | 1 | Jul 15, 2025 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $4.67 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.86 | +318.85% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.18 | +1,551.38% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.06 | +2,862.26% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $53.83 | +85.77% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.56 | +2,126.56% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $4.45 | +461.80% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.01 | +274.25% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.80 | +900.00% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.96 | +486.10% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.19
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $6.20
Upside: +190.32%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.52
Upside: +1,169.84%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.67
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.86
Upside: +318.85%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.18
Upside: +1,551.38%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.06
Upside: +2,862.26%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $53.83
Upside: +85.77%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.56
Upside: +2,126.56%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $4.45
Upside: +461.80%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.01
Upside: +274.25%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.80
Upside: +900.00%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.96
Upside: +486.10%